Brepocitinib
As of the edition of 20 October 2026, Brepocitinib is a small molecule: marketed, first approved in 2026 (US); acts on JAK1 and TYK2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Lisraya
- First approved
- 27 August 2026 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Roivant Sciences
- Registered trials
- 26, 0 stopped early
- Disease areas
- Skin and connective tissue; Immune system; Bones, joints and muscles; Blood and lymph; Digestive system; Eye
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Brepocitinib.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 9 | 0 | 0 |
| Phase 2 | 13 | 13 | 0 | 0 |
| Phase 3 | 4 | 1 | 3 | 0 |
| All trials | 26 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roivant Sciences | Originator and Lead sponsor of trials | 2022 to now |